HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
3,4-Diaminopyridin
Amifampridine · PYRIDINE-3,4-DIAMINE · 3,4-diamino-pyridin · 3,4-pyridinediamine · 3,4-DAP · NSC 521760 · Amipyridine · WLN: T6NJ CZ DZ
Identifikatoren & physikalische Daten
| CAS No. | 54-96-6 |
|---|---|
| Summenformel | C5H7N3 |
| Durchschnittliche Molmasse | 109,13 g/mol |
| Monoisotopische Masse | 109,06399722 g/mol |
| SMILES | Nc1ccncc1N |
| InChIKey | OYTKINVCDFNREN-UHFFFAOYSA-N |
| PubChem CID | 5918 |
| ChEMBL | CHEMBL354077 |
| ChEBI | CHEBI:135948 |
| EC No. | 200-220-9 |
| DTXSID | DTXSID6046715 |
| Lokaler Name | 3,4-Diaminopyridin |
Chemische & physikalische Eigenschaften
| XLogP | -0,5 |
|---|---|
| Polarare Oberfläche (TPSA) | 64,9 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 0 |
| Schwere Atome | 8 |
| Formalladung | 0 |
| Komplexität | 74,1 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
| Löslichkeit | freely soluble in water, and slightly soluble in solvents ethanol, methanol and acetic acid12.2 [ug/mL] (The mean of the results at pH 7.4)30g/l24 g/L (20 ºC) |
| Human Drugs | BreastfeedingLactationNeuromuscular AgentsPotassium Channel BlockersFDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| Schmelzpunkt | 216-218 °C (lit.) |
| Siedepunkt | 194.6°C (rough estimate) |
| Dichte | 1.1118 (rough estimate) |
| Brechungsindex | 1.5340 (estimate) |
| Flammpunkt | 240 °C |
| Lagerbedingungen | Store below +30°C. |
| Aggregatzustand | Crystalline Powder |
| pKa (Säurekonstante) | 9.17±0.12(Predicted) |
| Farbe | Brownish to brown-gray |
| Merck | 14,2986 |
| BRN | 110232 |
| InChI | InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8) |
| InChIKey | OYTKINVCDFNREN-UHFFFAOYSA-N |
| SMILES | C1=NC=CC(N)=C1N |
| CAS Datenbank | 54-96-6(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH300 (94.2%): Fatal if swallowed [Danger Acute toxicity, oral]P260, P261, P262, P264, P264+P265, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P319, P320, P321, P330, P332+P317, P337+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 52 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | 3,4-Diaminopyridine: HSNO Approval: HSR004250 Approved with controls |
| Hazard Classes and Categories | Acute Tox. 2 (94.2%) |
| Hepatotoxicity | Amifampridine has had limited clinical use, but adverse events have been largely neurologic and gastrointestinal. Serum ALT elevations were not reported in the prelicensure studies of amifampridine but were reported as occurring in a small proportion of patients in safety reviews by the Food and Drug Administration. Nevertheless, there have been no reports of clinically apparent liver injury associated with its use. Thus, liver injury from amifampridine must be rare if it occurs at all. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)AmifampridinevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| F | 10-23 |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 2811 6.1/PG 2 |
| Zollcode | 29333999 |
| RTECS-Nr. | US7600000 |
| R-Sätze (R) | 25-26-36/37/38 |
| Toxizität | LD50 orally in Rabbit: 47 mg/kg LD50 dermal Rabbit > 200 mg/kg |
| Gefahrensymbole | T+,T,Xi |
| hazard_note | Irritant |
| Sicherheitshinweise (S) | 26-28-36/37/39-45-37/39-28A-36 |
| Gefahrenklasse | 6.1Acute Tox. 2 InhalationAcute Tox. 2 OralAcute Tox. 3 DermalEye Irrit. 2 |
| Verpackungsgruppe | I |
| Lagerklasse | 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials |
| Selbstentzündungstemperatur | 480 °C |
Anwendungen & Verwendung
Verwenden
It is a potassium channel blocker in nerve terminals. It inhibits potassium channel efflux, increasing the duration of the action potential, which results in an increase in the duration of calcium channel opening and enhanced acetylcholine (ACh) release. Increased ACh availability at the motor end plate allows muscles to contract.